CHF562.80
0.39% today
SIX Swiss Exchange, Jul 01, 12:14 pm CET
ISIN
CH0013841017
Symbol
LONN
Sector
Industry

Lonza Stock price

CHF565.00
-4.20 0.74% 1M
+29.20 5.45% 6M
+29.20 5.45% YTD
+76.60 15.68% 1Y
+56.00 11.00% 3Y
+64.80 12.95% 5Y
+449.31 388.36% 10Y
+499.28 759.70% 20Y
SIX Swiss Exchange, Closing price Mon, Jun 30 2025
-1.60 0.28%
ISIN
CH0013841017
Symbol
LONN
Sector
Industry

Key metrics

Basic
Market capitalization
CHF38.7b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
Valuation (TTM | estimate)
P/E
63.34 | 34.08
P/S
5.89 | 4.95
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
CHF4.00
Yield 1Y | 5Y
0.71% | 0.65%
Growth 1Y | 5Y
0.00% | 7.78%
Payout 1Y | 3Y
44.84% | 33.68%
Increased
0 Years
Financials (TTM | estimate)
Revenue
CHF6.6b | CHF7.8b
EBITDA
CHF1.5b | CHF2.2b
EBIT
CHF1.3b
Net Income
CHF636.0m | -
Free Cash Flow
CHF-143.0m
Growth (TTM | estimate)
Revenue
-2.13% | 18.98%
EBITDA
- | 73.03%
EBIT
52.84%
Net Income
-2.75% | -
Free Cash Flow
52.49%
Margin (TTM | estimate)
Gross
32.86%
EBITDA
22.51% | 28.62%
EBIT
20.46%
Net
9.67% | -
Free Cash Flow
-2.18%
Financial Health
Equity Ratio
47.27%
Return on Equity
6.82%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
CHF8.92
FCF per Share
Short interest
-
Employees
17.83k
Rev per Employee
CHF370.00k
Show more

Create a Free Account to create an Lonza alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Lonza Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Lonza forecast:

26x Buy
84%
5x Hold
16%

Analyst Opinions

31 Analysts have issued a Lonza forecast:

Buy
84%
Hold
16%

Financial data from Lonza

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6,574 6,574
2% 2%
100%
- Direct Costs 4,414 4,414
7% 7%
67%
2,160 2,160
11% 11%
33%
- Selling and Administrative Expenses 1,010 1,010
6% 6%
15%
- Research and Development Expense - -
-
-
1,480 1,480
-
23%
- Depreciation and Amortization 135 135
-
2%
EBIT (Operating Income) EBIT 1,345 1,345
53% 53%
20%
Net Profit 636 636
3% 3%
10%

In millions CHF.

Don't miss a Thing! We will send you all news about Lonza directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lonza Stock News

AD HOC NEWS
about one month ago
Lonza Group AG / CH0013841017
AD HOC NEWS
about 2 months ago
Lonza Group AG / CH0013841017
More Lonza News

Company Profile

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Dr. Wienand
Employees 17,834
Founded 1897
Website www.lonza.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today